Simvastatin-Induced Meralgia Paresthetica

References

1. ↵
   Harney D, Patijn J. Meralgia paresthetica: diagnosis and management strategies. Pain Med 2007; 8: 669–77.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Van Slobbe AM, Bohnen AM, Bernsen RM, Koes BW, Bierma-Zeinstra SM. Incidence rates and determinants in meralgia paresthetica in general practice. J Neurol 2004; 251: 294–7.

   OpenUrlPubMedWeb of Science
3. ↵
   Ecker AD. Diagnosis of meralgia paresthetica. JAMA 1985; 253: 976.

   OpenUrlCrossRefPubMed
4. ↵
   Anderson J, Muhlestein JB, Bair T, et al. Do statins increase the risk of idiopathic polyneuropathy? Am J Cardiol 2005; 95: 1097–9.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Golomb BA, Evans MA. Statins adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8(6): 373–418.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001; 56: 931–3.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Corrao G, Zambon A, Bertu L, Botteri E, Leoni O, Contiero P. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an explanatory case-control study using automated database. J Epidemiol Community Health 2004; 58: 1047–51.

   OpenUrlAbstract/FREE Full Text
8. ↵
   Law M, Rudnicka AR. Statin safety:a systematic review. Am J Cardiol 2006; 97: 52C–60C.

   OpenUrlPubMedWeb of Science
9. ↵
   Gaist D, Jeppesen U, Andersen M, Rodriguez G, Hallas S, Sindrup SH. Statins and risk of polyneuropathy. Neurology 2003; 58: 1333–7.

   OpenUrl
10. ↵
    Shapiro BE, Preston DC. Entrapment and compressive neuropathies. Med Clin North Am 2009; 93: 285–315.

    OpenUrlCrossRefPubMed
11. ↵
    Ivanez V. Meralgia paresthetica is not always an entrapment neuropathy. J Fam Pract 2004; 53: 420.

    OpenUrlPubMed
12. ↵
    Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995; 58: 625–8.

    OpenUrlAbstract/FREE Full Text
13. ↵
    Peltier A, Russell JW. Advances in understanding drug-induced neuropathies. Drug Saf 2006; 29: 23–30.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2009; 9: 69–75.

    OpenUrlCrossRefPubMed
15. ↵
    Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 2003; 37: 274–8.

    OpenUrlAbstract/FREE Full Text
16. ↵
    Scola RH, Trentin AP, Germiniani FM, Piovesan EJ, Werneck LC. Simvastatin-induced mononeuropathy multiplex: case report. Arq Neuropsiquiatr 2004; 62: 540–2.

    OpenUrlPubMed
17. ↵
    Rajabally YA, Varakantam V, Abbott RJ. Disorder resembling Guillian-Barre syndrome on initiation of statin therapy. Muscle Nerve 2004; 30: 663–6.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Peripheral neuropathy and statins. Prescrire Int 2007; 16: 247–8.

    OpenUrlPubMed
19. ↵
    Brown W. Safety of statins. Curr Opin Lipidol 2008; 19: 558–62.

    OpenUrlCrossRefPubMed
20. ↵
    Formaglio M, Vial C. Statin induced neurpathy: myth or reality? Rev Neurol 2006; 162: 1286–9.

    OpenUrlPubMed
21. ↵
    Davis TME, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle diabetes study. Diabetologia 2008; 51: 562–6.

    OpenUrlCrossRefPubMedWeb of Science